Background
Methods
Data sources and Search strategy
Eligibility criteria
Data extraction
Quality assessment
Statistical analysis
Results
Literature search
Study characteristics
Author | Year | Country | # Participants | Study period | Patient category | Treatment | Comparator | Vitamin D dosage | Study design | Statistical methods | Follow-up duration months | ITT analysis | NOS scale |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teng et al. | 2003 | United States | 67399 | 1999 to 2001 | Prevalent HD patients | Paricalcitol | Calcitriol | NA | Historical cohort multicenter study | Baseline Cox model; as-treated analysis | 36 | no | 6 |
Shoji et al. | 2004 | Japan | 242 | 1992 to 1998 | Prevalent HD patients | Alfacalcidol | No treatment | NA | Prospective cohort single center study | Baseline Cox model | 76 | no | 9 |
Teng et al. | 2005 | United States | 51037 | 1996 to 1999 | Prevalent HD patients | Calcitriol or paricalcitol | No treatment | NA | Historical cohort multicenter study | Time-dependent Cox model; marginal structural model | 24 | yes | 6 |
Melamed et al. | 2006 | United States | 1007 | 1995 to 1998 | Incident HD and PD patients | Calcitriol | No treatment | NA | Prospective cohort multicenter study | Baseline and time-dependent Cox models | 48 | no | 5 |
Kalantar-Zadeh et al. | 2006 | United States | 58058 | 2001 to 2003 | Prevalent HD patients | Paricalcitol | No treatment | NA | Historical cohort multicenter study | Baseline and time-dependent Cox models | 24 | no | 7 |
Tentori et al. | 2006 | United States | 14967 | 1999 to 2004 | Prevalent HD patients | Calcitriol; paricalcitol; doxercalciferol | No treatment; each other | NA | Historical cohort multicenter study | Baseline and time-dependent Cox models; as treated analysis | 60 | yes | 7 |
Kovesdy et al. | 2008 | United States | 520 | 1990 to 2007 | CKD stage 2 to 4 patients | Calcitriol | No treatment | 1.75-3.5ug/week | Prospective cohort single center study | Baseline Cox model | 48 | no | 6 |
Naves-Diaz et al. | 2008 | Argentina; Brazil; Colombia; Chile; Mexico; Venezuela | 16004 | 2000 to 2004 | Prevalent HD patients | Calcitriol or alfacalcidol | No treatment | NA | Historical cohort multicenter study | Time-dependent Cox model | 54 | yes | 6 |
Shinaberger et al. | 2008 | United States | 34307 | 2001 to 2004 | Prevalent HD patients | Paricalcitol | No treatment | 1.7-30.8ug/week | Historical cohort multicenter study | Baseline Cox model | 30 | no | 7 |
Shoben et al. | 2008 | United States | 1418 | 1999 to 2007 | CKD stage 3 to 4 patients | Calcitriol | No treatment | Historical cohort multicenter study | Baseline Cox model; as-treated analysis | 48 | yes | 8 | |
Wolf et al. | 2008 | United States | 9303 | 2004 to 2005 | Incident HD patients | Calcitriol; paricalcitol; doxercalciferol | No treatment; stratified by race | NA | Prospective cohort multicenter study | Baseline Cox model | 12 | no | 5 |
Tentori et al. | 2009 | France; Germany; Italy; Japan; Spain; United Kingdom; United States; Australia; Belgium; Canada; New Zealand; Sweden | 38066 | 1996 to 2009 | Incident HD patients | Calcitriol; paricalcitol; doxercalciferol | No treatment; each other | NA | Prospective cohort multicenter study | Baseline and time-dependent Cox models; Marginal structural model | 30 | no | 5 |
Peter et al. | 2009 | United States | 193830 | 1999 to 2004 | Prevalent and incident HD | Calcitriol; paricalcitol; doxercalciferol | No treatment | 0.25-3.5ug/week* | Historical cohort multicenter study | Time-dependent Cox model | 63 | no | 6 |
Chang et al. | 2009 | Taiwan | 702 | 1993 to 2004 | Incident HD | Calcitriol | No treatment | 0.75-6.0ug/week | Retrospective cohort single center study | Baseline Cox model | 140 | no | 6 |
Konta et al. | 2010 | Japan | 466 | 2003 to 2008 | Incident HD | Calcitriol; falecalcitriol; maxacalcitol | No treatment | 1.1-5.1ug/week; 1.4-2.6ug/week; 2.6-5.4ug/week | Prospective cohort multicenter study | Baseline Cox model | 60 | no | 7 |
Sugiura et al. | 2010 | Japan | 665 | 1992 to 2008 | Incident HD | Alfacalcidol | No treatment | 1.75-3.5ug/week | Retrospective cohort single center study | Baseline Cox model | 132 | no | 6 |
Jean et al. | 2011 | France | 648 | 2005 to 2009 | Prevalent HD patients | Alfacalcidol | No treatment | 1.75-9ug/week | Prospective cohort multicenter study | Baseline Cox model | 42 | no | 5 |
Brancaccio et al. | 2011 | Italy | 2378 | 2006 to 2007 | Incident HD patients | Calcitriol; paricalcitol | No treatment | 1.9-3.3ug/week; 11.2-15.9ug/week | Prospective cohort multicenter study | Time-dependent Cox model | 18 | no | 5 |
Dierkes et al. | 2011 | Germany | 650 | NA | NA | Calcitrol; cholecalciferol | No treatment | NA | Prospective cohort multicenter study | NA | 24 | NA | NA |
Ogawa et al. | 2012 | Japan | 190 | 2005 to 2010 | Prevalent HD patients | Alfacalcidol | No treatment | 3.4-7.0ug/week | Prospective cohort single center study | Baseline Cox model | 60 | no | 9 |
Vitamin D and all-cause mortality
Patient group | # patients | Hazard ratio | # studies | I2, % |
---|---|---|---|---|
Patients with CKD not on dialysis | ||||
Crude all-cause mortality | 2603 | 0.61 (0.48–0.77) | 3 | 29.2 |
Adjusted all-cause mortality | 2603 | 0.59 (0.35–0.99) | 3 | 79 |
Patients with ESRD on dialysis | ||||
Crude all-cause mortality | 109628 | 0.65 (0.58–0.73) | 11 | 95 |
Adjusted all-cause mortality | 66639 | 0.80 (0.68–0.94) | 6 | 94.4 |
Vitamin D and cardiovascular mortality
Patient groups | # patients | Hazard ratio | # studies | I2, % |
---|---|---|---|---|
Crude cardiovascular mortality using baseline Cox model | ||||
Alfacalcitol vs no treatment | 432 | 0.37 (0.25–0.55) | 2 | 0 |
Calcitrol vs no treatment | 1889 | 0.57 (0.46–0.71) | 1 | NA |
Paricalcitol vs no treatment | 1230 | 0.31 (0.22–0.44) | 1 | NA |
Overall | 3551 | 0.41 (0.28–0.59) | 4 | 69.9 |
Adjusted cardiovascular mortality using baseline Cox model | ||||
Any vitamin D vs no treatment | 466 | 0.59 (0.19–1.82) | 2 | 68.6 |
Alfacalcitol vs no treatment | 665 | 0.45 (0.14–1.47) | 1 | NA |
Calcitrol vs no treatment | 1889 | 0.63 (0.50–0.79) | 1 | NA |
Paricalcitol vs no treatment | 1230 | 0.43 (0.29–0.63) | 1 | NA |
Overall | 4250 | 0.59 (0.41–0.86) | 5 | 83.6 |
Calcitriol vs paricalcitol and all-cause mortality
Patient group | # patients | Hazard ratio | # studies | I2, % |
---|---|---|---|---|
Crude baseline Cox model | 75130 | 0.80 (0.75–0.86) | 2 | 0 |
Adjusted baseline Cox case mixed model | 16008 | 0.89 (0.79–1.00) | 3 | 62.9 |
Adjusted baseline Cox case mixed and MICS model | 14384 | 0.95 (0.91–0.99) | 2 | 0 |
Vitamin D dosage and all-cause mortality
Investigator | # patients | Follow up (months) | Dosage (ug/week) | Mean dosage (ug/week) | Hazard ratio | 95% CI |
---|---|---|---|---|---|---|
Calcitrol | ||||||
Naves-Diaz et al. | 1304 | 54 | <1.75 | 1.05 | 0.46 | 0.37–0.53 |
Naves-Diaz et al. | 1053 | 54 | 1.75-3.5 | 2.38 | 0.58 | 0.49–0.70 |
Naves-Diaz et al. | 432 | 54 | 3.5-7.0 | 4.69 | 0.64 | 0.50–0.83 |
Naves-Diaz et al. | 184 | 54 | >7.0 | 11.83 | 0.83 | 0.58–1.19 |
Paricalcitol | ||||||
Kalantar-Zadeh et al. | 5288 | 24 | 1.0-5.0 | NA | 0.53 | 0.50–0.57 |
Kalantar-Zadeh et al. | 11965 | 24 | 5.0-10.0 | NA | 0.54 | 0.51–0.57 |
Kalantar-Zadeh et al. | 8326 | 24 | 10.0-15.0 | NA | 0.54 | 0.51–0.57 |
Kalantar-Zadeh et al. | 11816 | 24 | >15.0 | NA | 0.73 | 0.69–0.77 |
Shinaberger et al. | 9575 | 30 | 1.7-20.1 | 10.9 | 0.93 | 0.89–0.97 |
Shinaberger et al. | 8277 | 30 | 4.6-25.8 | 15.2 | 0.88 | 0.84–0.94 |
Shinaberger et al. | 5875 | 30 | 6.4-30.8 | 18.6 | 0.88 | 0.84–0.93 |